Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy

Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy

Introduction. Standard treatment for patients with chronic hepatitis C genotype 1 (CHC G-1) infection includes pegylated interferon plus ribavirin (PEG-RBV) for 48 weeks. Shorter treatment regimen would be more acceptable due to lower cost and fewer side-effects. We aimed to compare the efficacy of...

Full description

Bibliographic Details
Main Authors:	Ajit Sood, M.D., D.M., Vandana Midha, Omesh Goyal
Format:	Article
Language:	English
Published:	Elsevier 2014-09-01
Series:	Annals of Hepatology
Subjects:	Early virological response Shorter therapy Sustained virological response Thirty-six weeks
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268119312499

Similar Items

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection
by: Mona H Ismail
Published: (2013-01-01)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
by: Zheng C, et al.
Published: (2019-04-01)

Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin
by: Pei-yuan Su, et al.
Published: (2016-07-01)

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
by: Guo Xiaoyan, et al.
Published: (2012-06-01)

Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin
by: Yi-Hao Yen, et al.
Published: (2015-07-01)

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
by: Ming-Chao Tsai, et al.
Published: (2009-09-01)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
by: Sung Yong Han, et al.
Published: (2021-05-01)

Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy
by: Hu CC, et al.
Published: (2018-04-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

The Sustained Virologic Response and Adverse Effects of Peg Interferon Alfa and Ribavirin in the Treatment of Patients with Chronic Hepatitis C: A Study from Iran
by: Simindokht Shoaei, et al.
Published: (2017-10-01)

TREATMENTS OF HEPATITIS C VIRUS LIVER CIRRHOSIS WITH PEGYLAT INTERFERON-RIBAVIRIN AND INTERFERON FREE – COMPARATIVE STUDY
by: S.A. Florescu, et al.
Published: (2016-12-01)

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial
by: Miguel Ángel Jiménez-Luévano, et al.
Published: (2013-03-01)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
by: Andréa Marques Vieira da Silva, et al.
Published: (2021-07-01)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
by: Fabien Zoulim, et al.
Published: (2018-01-01)

Identification of diverse defense mechanisms in rainbow trout red blood cells in response to halted replication of VHS virus [version 2; referees: 1 approved, 2 approved with reservations]
by: Ivan Nombela, et al.
Published: (2018-02-01)

IL-15 enhances cross-reactive antibody recall responses to seasonal H3 influenza viruses in vitro [version 1; referees: 2 approved]
by: Junqiong Huang, et al.
Published: (2017-11-01)

PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort [version 1; referees: 2 approved]
by: Colin P. Sharp, et al.
Published: (2017-04-01)

Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report
by: Ken Kurokawa, et al.
Published: (2020-05-01)

The Future of Work - Investigating the Case for Intervention in Working Time Policy in New Zealand
by: Williams, Christian
Published: (2011)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience
by: Nabiha Faisal, MD, FCPS, et al.
Published: (2014-09-01)

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
by: Brunda Ganneru, et al.
Published: (2021-04-01)

A Multicenter Study To Evaluate The Safety And Efficacy Of Heber On (Interferon Alfa-2b) In Combination With Ribavirin For The Treatment Of Chronic Hepatitis C In Iran
by: H. Mirmomen, et al.
Published: (2005-05-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens
by: Hu Li, et al.
Published: (2019-08-01)

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
by: Zubia Jamil, et al.
Published: (2018-05-01)

Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
by: Ng KJ, et al.
Published: (2016-08-01)

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients
by: Crina Fofiu, et al.
Published: (2019-01-01)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
by: Tatsuo Kanda, et al.
Published: (2015-07-01)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
by: Osamu Yokosuka, et al.
Published: (2012-08-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients
by: Yan-Di Xie, et al.
Published: (2017-01-01)

Infectious pancreatic necrosis virus triggers antiviral immune response in rainbow trout red blood cells, despite not being infective [version 2; referees: 2 approved]
by: Ivan Nombela, et al.
Published: (2017-12-01)

Regulation of Adenoviral Gene Expression by the L4-33K and L4-22K Proteins
by: Backström, Ellenor
Published: (2009)

The Norovirus Puzzle : Characterization of human and bovine norovirus susceptibility patterns
by: Vildevall, Malin
Published: (2011)

Cellular and Viral Factors that Control Human Papillomavirus Type 16 Late Gene Expression
by: Somberg, Monika
Published: (2011)

Host genetic risk factors to viral diseases - a double-edged sword : Studies of norovirus and tick-borne encephalitis virus
by: Kindberg, Elin
Published: (2010)

Genomic Organization and Capsid Architecture of Ljungan Virus : a Novel Member of the Picornaviridae
by: Johansson, Susanne
Published: (2002)

A regional perspective on the French 35 hour week policy : tracing policy-making and implementation from nord-Pas-de-Calais to Paris
by: Flutter, Chlöe
Published: (2003)

Interferon-induced transmembrane proteins inhibit human immunodeficiency virus type 1 replication
by: Lu, Jennifer
Published: (2010)